Wall Street Zen upgraded shares of YD Bio (NASDAQ:YDES – Free Report) to a hold rating in a research note issued to investors on Saturday morning,Wall Street Zen reports.
YD Bio Stock Up 20.1%
Shares of NASDAQ:YDES opened at $5.73 on Friday. YD Bio has a 12 month low of $1.70 and a 12 month high of $22.00. The company has a 50-day moving average price of $3.32 and a 200 day moving average price of $4.19.
YD Bio (NASDAQ:YDES – Get Free Report) last issued its quarterly earnings data on Tuesday, September 1st. The biotechnology company reported $0.05 earnings per share for the quarter. The company had revenue of $0.42 million for the quarter.
Institutional Inflows and Outflows
A hedge fund recently raised its position in YD Bio stock. Cypress Capital Management LLC WY raised its position in shares of YD Bio Limited (NASDAQ:YDES – Free Report) by 9.8% during the second quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 33,690 shares of the biotechnology company’s stock after acquiring an additional 3,000 shares during the period. Cypress Capital Management LLC WY’s holdings in YD Bio were worth $76,000 as of its most recent filing with the Securities & Exchange Commission.
YD Bio Company Profile
YD Bio Limited is a biotechnology company advancing DNA methylation-based cancer detection technology and ophthalmologic innovations.
Featured Articles
- Five stocks we like better than YD Bio
- 3 Defense Stocks Riding Nuclear, Missile, and Aerospace Demand
- SoFi Is Bypassing the Banking Bottleneck With Stablecoin Settlement
- These 3 Overlooked Stocks Have Big Money Behind Them
- Darden Restaurants Serves Up Fresh Catalysts for a Stock Price Rally
Receive News & Ratings for YD Bio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for YD Bio and related companies with MarketBeat.com's FREE daily email newsletter.
